Credits Earned (2024) Crédits obtenus

Redeem Prepaid Membership

Tools for Practice Outils pour la pratique


#87 Daily multivitamins to reduce mortality, cardiovascular disease, and cancer


CLINICAL QUESTION
QUESTION CLINIQUE
Does daily multivitamin supplementation reduce mortality, cardiovascular disease (CVD), and/or cancer?


BOTTOM LINE
RÉSULTAT FINAL
Present evidence does not support the routine use of multivitamins to reduce mortality, cardiovascular disease, or cancer for people in developed countries.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
A meta-analysis and one Randomized Controlled Trial (RCT). Meta-analysis1 of 21 RCTs (including RCT below) with 91,074 patients (54% males) randomized to multivitamins or placebo for 3.5 years. Most are primary prevention studies from Europe or North America
  • No effect on overall mortality: Relative Risk (RR)=0.98 (0.94-1.02).
    • No effect on cancer mortality: RR=0.96 (0.88-1.04).
    • No effect on CVD mortality: RR=1.01 (0.93-1.09).
    • Multiple subgroup testing found no differences.
  • No evidence of publication bias or meaningful heterogeneity.
Physicians’ Health Study II: Heavily publicized RCT2,3 of 14,641 men (mean age 64.3) randomized to Centrum Silver™ or placebo, followed 11.2 years.
  • No effect on overall mortality: Hazard Ratio (HR)=0.94 (0.88-1.02).
    • No effect on cancer mortality: HR=0.88 (0.77-1.01).
    • No effect on CVD mortality: HR=0.95 (0.83-1.09).
    • No effect on CVD events: HR=1.01 (0.91-1.10).
    • Reduced cancer incidence: HR=0.92 (0.86-0.998).
      • These were adjusted (for unclear reasons).
      • Unadjusted is not significant RR=0.94 (0.87-1.003).
  • Multiple issues: Lots of exclusion including run-in to remove non-compliant patients, adjustments (without clear reason) always in favor of multivitamins.
Context:
  • Multiple cohort studies have found no mortality reduction with multivitamins.
  • Vitamin supplementation may help reduce overall mortality in undernourished populations (like rural China). 8
    • However, in this RCT8 of four different vitamin interventions, only one reduced mortality RR=0.91 (0.84-0.99).
  • Meta-analyses of different vitamin components on mortality:
    • B-Vitamins:9 No effect.
    • Anti-oxidants:10 Increase mortality RR=1.04 (1.01-1.07).
      • Increase with vitamin E, beta-carotene and high-dose vitamin A.
      • No effect from vitamin C and selenium.
    • Vitamin D:11 Decrease mortality RR=0.97 (0.94-1.00)
    • Increases and decreases are small [Numbers Needed to Harm (NNH) or treat around 200 over five years].


Latest Tools for Practice
Derniers outils pour la pratique

#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?

What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
Read Lire 0.25 credits available Crédits disponibles

#377 How to slow the flow IV: Combined oral contraceptives

In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
Read Lire 0.25 credits available Crédits disponibles

#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)

What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • G. Michael Allan MD CCFP
  • Mayank Singal MD CCFP

1. Macpherson H, Pipingas A, Pase MP. Am J Clin Nutr. 2012 Dec 19. [Epub ahead of print]

2. Gaziano JM, Sesso HD, Christen WG, et al. JAMA. 2012; 308:1871-80.

3. Sesso HD, Christen WG, Bubes V, et al. JAMA. 2012; 308:1751-60.

4. Neuhouser ML, Wassertheil-Smoller S, Thomson C, et al. Arch Intern Med. 2009; 169:294-304.

5. Park SY, Murphy SP, Wilkens LR, et al. Am J Epidemiol. 2011; 173:906-14.

6. Li K, Kaaks R, Linseisen J, et al. Eur J Nutr. 2012; 51:407-13.

7. Watkins ML, Erickson JD, Thun MJ, et al. Am J Epidemiol. 2000; 152:149-62.

8. Blot WJ, Li JY, Taylor PR, et al. J Natl Cancer Inst. 1993; 85:1483-92.

9. Clarke R, Halsey J, Lewington S, et al. Arch Intern Med. 2010; 170:1622-31.

10. Bjelakovic G, Nikolova D, Gluud LL, et al. Cochrane Database Syst Rev. 2012; 3:CD007176.

11. Bjelakovic G, Gluud LL, Nikolova D, et al. Cochrane Database Syst Rev. 2011; 7:CD007470.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.

Most recent review: 05/08/2016

By: Ricky D. Turgeon BSc(Pharm) ACPR PharmD

Comments:

Evidence Updated: No new evidence; Bottom Line: No change.

Learning at a glance
Yearly credits
Acquired ()
Your content by topic
Cardiology Dermatology Emergency
My Bookmarks